In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Foamix Pharma (NASDAQ: FOMX), with a price target of $12. The company’s shares closed on Friday at $5.80.
According to TipRanks.com, Selvaraju is a 3-star analyst with an average return of 1.2% and a 44.4% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Currently, the analyst consensus on Foamix Pharma is a Moderate Buy with an average price target of $10.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.45 and a one-year low of $4.34. Currently, Foamix Pharma has an average volume of 92.32K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Foamix Pharmaceuticals Ltd. is a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel.
